Novartis in Society ESG Report
- Our Impact
Novartis in Society ESG Report
We aim to take real, measurable and reportable action on key environmental, social and governance topics.
“We aspire to be a leader on environmental, social and governance topics and to build trust with society. In the long run, that’s what will enable us to continue reimagining medicine.”
Vas Narasimhan, CEO Novartis
For more information on our key corporate responsibility issues click here.
Ethical Standards
We are committed to meeting the highest ethical standards in what we do, and we are taking steps to earn and maintain the trust of patients, associates, partners, shareholders and society.
Access to Healthcare
As a global medicines company, we embrace our responsibility to society to help ensure our innovative treatments benefit more people who need them, no matter where they live.
Global Health
Novartis has a long heritage in tackling infectious and neglected tropical diseases. We continue to play a significant role in global movements to end leprosy and malaria, while initiating new efforts to tackle sickle cell disease and Chagas disease.
Responsible Citizenship
Strong leadership is needed now more than ever to move beyond business as usual and catalyze a global response to complex societal challenges like climate change.
Performance indicators, data tables, appendixes
- About this report (PDF p.50)
- Performance indicators (PDF p.51)
- Novartis GRI content index (PDF p.55)
- Material topic boundaries (PDF p.59)
- Materiality assessment issue cluster and topic definitions (PDF p.61)
- External initiatives and membership of associations (PDF p.63)
- Supplier spend (PDF p.64)
- Measuring and valuing our impact (PDF p.65)